Real-World Analysis Show Takeda's Alofisel Clinical Remission Rate At Six-Months


Takeda Pharmaceutical Co Ltd TAK announced the first six-month interim analysis results from INSPIRE study evaluating the Real-World Effectiveness and Safety of Alofisel (darvadstrocel).

  • The study demonstrated clinical remission in 65% of patients in both cohorts evaluated at six months, with Crohn's disease (CD) and complex perianal fistulas.
  • Data were presented at the European Crohn's and Colitis Organisation (ECCO) 2022 Congress.
  • Clinical response was observed in 73% (57/78) and 74% (51/69) of patients in the All Treated (AT) and Treated Per Protocol (PP) cohorts, respectively.
  • Also See: FDA Rejects Takeda's Eosinophilic Esophagitis Candidate, Asks For Additional Study.
  • Changes in CD activity post-treatment were minimal. Of the 205 patients with complete treatment data, 20% (41/205) had one or more adverse events, and 9.3% (19/205) had one or more serious adverse events.
  • There were no reports of ectopic tissue formation and no deaths.
  • Price Action: TAK shares are down 0.07% at $15.25 during the market session on the last check Friday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareGeneralBriefsCrohn's Disease
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!